Page last updated: 2024-09-05

erlotinib hydrochloride and at 13387

erlotinib hydrochloride has been researched along with at 13387 in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (at 13387)	Trials (at 13387)	Recent Studies (post-2010) (at 13387)
4,353	786	3,033	59	4	57

Protein Interaction Comparison

Protein	Taxonomy	at 13387 (IC50)
Heat shock protein HSP 90-alpha	Homo sapiens (human)	0.0437
Heat shock protein HSP 90-beta	Homo sapiens (human)	0.138
Endoplasmin	Homo sapiens (human)	0.022
Endoplasmin	Canis lupus familiaris (dog)	0.013

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Courtin, A; Hearn, K; Lyons, JF; Saini, HK; Smyth, T; Thompson, NT; Wallis, NG	1
Frankel, P; Gandara, DR; Keer, HN; Kelly, KA; Lara, PN; Longmate, J; Mack, PC; Newman, EM; Raymond, VM; Reckamp, KL; Riess, JW; Weipert, CM	1

Trials

1 trial(s) available for erlotinib hydrochloride and at 13387

Article	Year
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clinical lung cancer, 2021, Volume: 22, Issue:6 Topics: Aged; Benzamides; California; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isoindoles; Lactates; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies	2021

Other Studies

1 other study(ies) available for erlotinib hydrochloride and at 13387

Article	Year
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. British journal of cancer, 2016, Oct-25, Volume: 115, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays	2016

Article

Year

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.

British journal of cancer, 2016, Oct-25, Volume: 115, Issue:9

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays

2016